Big Buttons

• Lilly intervenes in OFA lawsuit against FDA

  Lilly says the FDA isn’t allowed to decide when compounders can compound FDA-approved drugs. read more →

• Reason #1 to come to the APC Owner Summit

  "Turning Science into Stories" with Andrew Buck will teach you how to turn facts into stories that will connect with both rational and emotional audiences. read more →

• FDA releases final interim guidance on bulk drug substances for both 503As and 503Bs 

  This new guidance supersedes the 2017 versions of the same titles. read more →

• Why you need to sign up for an APC Package Deal — and why now is the right time

  The beginning of the calendar year is the best time to be grab a package deal. read more →

• FDA doubles down: Tirzepatide is off shortage

  ...but that doesn't mean the issue is completely settled. read more →

• A couple of state updates

  Good news from Alabama, but a problem in Massachusetts read more →

• Defending GLP-1 compounding

  The latest letters APC's been sending to oppose efforts to restrict compounding read more →

• Thumbs-up for FDA crackdown

  APC was thrilled when the FDA announced it was taking action against illegal online businesses claiming to sell “research-grade” compounds. read more →

More News

Upcoming Events

January 16: APC CE webinar: Survey of State Compounding Law Changes 2024 and Proposed 2025 Changes

February 20: APC CE webinar: Navigating Marketing and 503B Sourcing: Best Practices for Compounding Pharmacies

March 14–16, 2025: APC Owner Summit, Destin, FL

March 27–29, 2025: Personalized Medicine Course II: Gastroenterology, Infectious Disease, Dermatology; Houston, TX (in-person and online option)

September 16–17, 2025: APC Compounders on Capitol Hill, Washington, DC

November 7–9, 2025: Personalized Medicine Course III: Memory Maintenance, Neurology, Psychiatry, How to Interpret Functional Medicine Labs; Scottsdale, AZ

The Latest Resources for Compounders

• Best Practices for Compounding Shortage Drugs
• Best Practices for Marketing Compounded Medications
• Best Practices for Compounding Ketamine
• Best Practices for Clinic Direct Billing (Office Pay)
• Brief on Compounded GLP-1 Drugs and Patient Adverse Events
• Statement on Peptide Compounding
• Statement on Constructive Transfer

Click here for more resources for compounding professionals

APC In the News

Politico covers ongoing tirzepatide suit:

Eli Lilly has weighed in, and APC rebuts the company's contentions

Morning Edition updates its GLP-1 story:

NPR ran an updated story on the 'battle' between compounders and drug makers over GLP-1 weight-loss drugs.

Endpoints shares our FDA letter:

We're getting more coverage from larger outlets.

Legit or not? ABC News looks at the difference:

ABC News turned to APC for insight into the difference between legit GLP-1 compounders and fly-by-night 'wellness' sites.

Covering the GLP-1 shortage:

Reuters did an excellent job updating the status of the Wegovy shortage.

NPR hits the GLP-1 nail on the head:

National Public Radio did a spot-on job explaining the current situation with compounded GLP-1 drugs.

Not holding back:

We pull no punches in this article about Novo's latest shenanigans

Video appearance: APC talks the legal issues:

APC CEO Scott Brunner was a guest on "On The Pen" — a YouTube channel dedicated to all things GLP-1.

Click here for more examples of APC in the news

Support Compounding

Our Patrons